{"schema_version":"1.0","type":"article","title":"處方魚油Vascepa讓大腸癌多活，難換藥證","url":"https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2.md","lang":"zh-Hant","date":"2026-10-29","publish_at":"2026-10-29T08:00:00+08:00","updated_at":"2026-10-29","category":"醫學大會","topic":"醫學大會","tags":["魚油","大腸癌","Vascepa","Amarin","ESMO 2026"],"summary":"大家以為魚油不防癌。ESMO 上，一顆處方魚油讓大腸癌肝轉移病人五年存活從 45.1% 拉到 62.0%。但癌症復發速度一樣、安慰劑又是七年前被罵過的礦物油，這份數據換不到藥證。","key_points":["Amarin 在 2027 年 12 月 31 日前不會向 FDA 或 EMA 遞交 Vascepa（icosapent ethyl）用於大腸癌肝轉移的上市申請，因為 2026 年 10 月 25 日 ESMO 發表的 EMT2 三期主要終點無惡化存活失敗（風險比 0.89，p=0.33）。","EMT2 收治 418 位要切除肝轉移的大腸癌病人，每天 4 公克 Vascepa 組五年存活率 62.0%、礦物油安慰劑組 45.1%，死亡風險比 0.68（p=0.030），出血與心房顫動沒有增加。","EMT2 每天 EPA 4,000 毫克，是一顆市售 1,000 毫克魚油（約 180 毫克 EPA）的 22 倍；每天 EPA 460 毫克的 VITAL 試驗（25,871 人）沒有降低癌症風險（風險比 1.03）。"],"facts":[{"claim":"EMT2 三期隨機分組人數","value":418,"unit":"人","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 收案的英格蘭與威爾斯肝膽外科中心數","value":13,"unit":"家","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 Vascepa 每日劑量","value":4,"unit":"公克","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 Vascepa 組中位無惡化存活","value":13.5,"unit":"月","as_of":"2026-10-25","source":"https://oncodaily.com/gastrointestinal-oncology/emt2-esmo-2026"},{"claim":"EMT2 安慰劑組中位無惡化存活","value":12.9,"unit":"月","as_of":"2026-10-25","source":"https://oncodaily.com/gastrointestinal-oncology/emt2-esmo-2026"},{"claim":"EMT2 無惡化存活風險比（主要終點，p=0.33）","value":0.89,"unit":"HR","as_of":"2026-10-25","source":"https://oncodaily.com/gastrointestinal-oncology/emt2-esmo-2026"},{"claim":"EMT2 Vascepa 組估計五年總存活率","value":62,"unit":"%","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 安慰劑組估計五年總存活率","value":45.1,"unit":"%","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"EMT2 總存活風險比（p=0.030）","value":0.68,"unit":"HR","as_of":"2026-10-25","source":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"claim":"Amarin 2026 年第二季總營收","value":42.2,"unit":"百萬美元","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"Amarin 2026 年第二季總營收年減幅","value":42,"unit":"%","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"Amarin 2026 年第二季美國產品營收","value":32.2,"unit":"百萬美元","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"Amarin 2025 年第二季營收內含 Recordati 首付款","value":25,"unit":"百萬美元","as_of":"2025-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"Amarin 2026 年 6 月 30 日現金","value":314.6,"unit":"百萬美元","as_of":"2026-06-30","source":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"claim":"STRENGTH（Epanova）收案人數","value":13078,"unit":"人","as_of":"2020-11-15","source":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"claim":"STRENGTH 心血管事件風險比","value":0.99,"unit":"HR","as_of":"2020-11-15","source":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"claim":"REDUCE-IT 安慰劑組 hsCRP 上升","value":32,"unit":"%","as_of":"2020-11-15","source":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"claim":"REDUCE-IT 安慰劑組 LDL 上升","value":10.2,"unit":"%","as_of":"2020-11-15","source":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"claim":"REDUCE-IT 主要心血管事件相對降低","value":25,"unit":"%","as_of":"2020-09-16","source":"https://www.ajmc.com/view/the-reduce-it-study-and-cv-risk"},{"claim":"VITAL 受試者人數","value":25871,"unit":"人","as_of":"2019-03-26","source":"https://evidence.nihr.ac.uk/alert/one-gram-a-day-of-omega-3-supplements-does-not-reduce-the-risk-of-cancer-or-cardiovascular-disease/"},{"claim":"VITAL 每日 EPA 劑量","value":460,"unit":"毫克","as_of":"2019-03-26","source":"https://evidence.nihr.ac.uk/alert/one-gram-a-day-of-omega-3-supplements-does-not-reduce-the-risk-of-cancer-or-cardiovascular-disease/"},{"claim":"VITAL 魚油組侵襲性癌症風險比","value":1.03,"unit":"HR","as_of":"2019-03-26","source":"https://evidence.nihr.ac.uk/alert/one-gram-a-day-of-omega-3-supplements-does-not-reduce-the-risk-of-cancer-or-cardiovascular-disease/"},{"claim":"市售 1,000 毫克魚油軟膠囊每顆 EPA 含量","value":180,"unit":"毫克","as_of":"2026-10-26","source":"https://german-drugstore.com/product/doppelherz-omega-3-sea-fish-oil-80-capsules/"},{"claim":"億騰醫藥取得 Vascepa 中國、港澳與台灣權利的交易總值上限","value":169,"unit":"百萬美元","as_of":"2015-02-27","source":"https://www.biospace.com/b-eddingpharm-b-gains-china-rights-to-amarin-s-omega-3-product-in-169-million-deal"},{"claim":"台灣 2023 年新診斷癌症人數（大腸癌居第二）","value":"逾13.8萬","unit":"人","as_of":"2025-12-30","source":"https://news.pts.org.tw/article/788225"}],"sections":["01｜五年多活 17 個百分點，癌症卻一樣快復發","02｜同一種礦物油，七年前就被質疑過","03｜Amarin 需要這個故事，比病人還急","04｜台灣藥局架上的魚油，不是這顆藥","05｜62% 對 45%，是一張邀請函","參考資料"],"references":[{"title":"Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2","source":"Amarin（GlobeNewswire","date":"2026-10-25","url":"https://www.globenewswire.com/news-release/2026/10/25/3387729/18362/en/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2-emt2-evaluating-vazkepa-vascepa-icosapent-ethyl-capsules-on-top-of-standard-of-care-treat.html"},{"title":"Amarin Provides Update on EMT2: A colorectal cancer trial missed its goal, but estimated 5-year survival was 62%","source":"StockTitan","date":"2026-10-25","url":"https://www.stocktitan.net/news/AMRN/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-dls9jlkhdt8y.html"},{"title":"EMT2 at ESMO 2026: Eicosapentaenoic Acid After Colorectal Cancer Liver Metastasis Resection","source":"OncoDaily","date":"2026-10-25","url":"https://oncodaily.com/gastrointestinal-oncology/emt2-esmo-2026"},{"title":"EPA for Metastasis Trial 2 (NCT03428477","source":"ClinicalTrials.gov","date":"2026-10-26","url":"https://clinicaltrials.gov/study/NCT03428477"},{"title":"Amarin Reports Second Quarter 2026 Financial Results (Exhibit 99.1, Form 8-K","source":"SEC EDGAR","date":"2026-07-29","url":"https://www.sec.gov/Archives/edgar/data/0000897448/000119312526323841/amrn-ex99_1.htm"},{"title":"Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT","source":"TCTMD","date":"2020-11-15","url":"https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it"},{"title":"The REDUCE-IT Study and CV Risk","source":"AJMC","date":"2020-09-16","url":"https://www.ajmc.com/view/the-reduce-it-study-and-cv-risk"},{"title":"One gram a day of omega-3 supplements does not reduce the risk of cancer or cardiovascular disease (VITAL","source":"NIHR Evidence","date":"2019-03-26","url":"https://evidence.nihr.ac.uk/alert/one-gram-a-day-of-omega-3-supplements-does-not-reduce-the-risk-of-cancer-or-cardiovascular-disease/"},{"title":"Red blood cell EPA levels and survival in the EMT trial (Prostaglandins, Leukotrienes and Essential Fatty Acids 115:60–66","source":"White Rose Research Online","date":"2016-12-01","url":"https://eprints.whiterose.ac.uk/105833"},{"title":"112 年癌症登記報告：新診斷癌症逾 13.8 萬人，大腸癌居第二","source":"公視新聞網","date":"2025-12-30","url":"https://news.pts.org.tw/article/788225"},{"title":"Eddingpharm gains China rights to Amarin's omega-3 product in $169 million deal","source":"BioSpace","date":"2015-02-27","url":"https://www.biospace.com/b-eddingpharm-b-gains-china-rights-to-amarin-s-omega-3-product-in-169-million-deal"},{"title":"Doppelherz Omega-3 Sea Fish Oil 1000 (180 mg EPA + 120 mg DHA per capsule","source":"German Drugstore","date":"2026-10-26","url":"https://german-drugstore.com/product/doppelherz-omega-3-sea-fish-oil-80-capsules/"}],"images":[{"alt":"圖1｜Vascepa 在肝轉移病人身上做了什麼","url":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2/figure-01.png"},{"alt":"圖2｜EMT2 兩個終點，結果相反","url":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2/figure-02.png"},{"alt":"圖3｜四個魚油大型試驗，對照組決定了結論","url":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2/figure-03.png"},{"alt":"圖4｜EPA 劑量差 22 倍","url":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-29）。處方魚油Vascepa讓大腸癌多活，難換藥證。https://drugnews.com.tw/articles/2026-10-29-vascepa-fish-oil-colorectal-cancer-liver-metastasis-emt2.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"fb_body":"大腸癌肝轉移的病人，每天吃 4 公克處方魚油，五年存活率 62.0%；吃安慰劑的 45.1%。\n\n這是 10 月 25 日 ESMO 大會上的 EMT2 三期試驗，藥是 Amarin 的 Vascepa。\n\n七年前，VITAL 試驗讓兩萬五千多人每天吃 1 公克魚油，癌症一點都沒少。魚油不防癌，幾乎成了定論。\n\n但 EMT2 的數字有兩個問題。\n\n第一，主要終點沒過：兩組癌症復發一樣快（13.5 對 12.9 個月）。病人活得久，癌症卻沒有長得比較慢。\n\n第二，安慰劑用的是礦物油。2018 年 Amarin 的心臟試驗 REDUCE-IT 也用礦物油，被批評讓對照組的壞膽固醇和發炎指標上升；AstraZeneca 改用玉米油做同類試驗，結果打平。\n\n所以這份數據換不到藥證。到 2027 年底，Amarin 不會向 FDA 或 EMA 送出大腸癌申請，它需要一個以存活為主要終點的新試驗。\n\n還有一件事：EMT2 每天 EPA 4,000 毫克，市售 1,000 毫克魚油一顆大約 180 毫克 EPA，差了 22 倍。藥局架上的魚油，不是這顆藥。\n\n你覺得礦物油安慰劑，能解釋這三成的死亡差距嗎？\n\n追蹤藥時事，每天拆解一筆全球醫藥大事背後的商業邏輯。","relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}